Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Completed 6 Months Study	STARTED	Daclizumab	216
Completed 6 Months Study	STARTED	Placebo	218
Completed 6 Months Study	COMPLETED	Daclizumab	165
Completed 6 Months Study	COMPLETED	Placebo	170
Completed 6 Months Study	NOT COMPLETED	Daclizumab	51
Completed 6 Months Study	NOT COMPLETED	Placebo	48
Completed 12 Months Study	STARTED	Daclizumab	165
Completed 12 Months Study	STARTED	Placebo	170
Completed 12 Months Study	COMPLETED	Daclizumab	162
Completed 12 Months Study	COMPLETED	Placebo	167
Completed 12 Months Study	NOT COMPLETED	Daclizumab	3
Completed 12 Months Study	NOT COMPLETED	Placebo	3

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00048165/flow